Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Melanoma 11Carcinoma, Renal Cell 8Lymphoma 7Neoplasm Metastasis 6Nasopharyngeal Carcinoma 6Lung Neoplasms 6Hematologic Neoplasms 5Glioblastoma 5Anus Neoplasms 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Multiple Myeloma 4Leukemia, Myeloid, Acute 4Hodgkin Disease 4Glioma 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Basal Cell 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma, Kaposi 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3HIV Infections 3Gliosarcoma 3Esophageal Neoplasms 3

Interventions

Specimen Handling 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Xeroderma Pigmentosum × Nivolumab × Clear all
NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

National Cancer Institute (NCI)

Phase 1 Withdrawn
CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡